Tesamorelin: The FDA-Approved GHRH Analog
Tesamorelin (trade name Egrifta) is a synthetic analog of human growth hormone-releasing hormone (GHRH) consisting of 44 amino acids — the full-length human GHRH(1-44) sequence with a trans-3-hexenoic acid modification at the N-terminus. Developed by Theratechnologies Inc., Tesamorelin received FDA approval in 2010 for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy (Falutz et al., 2007).
As the only FDA-approved GHRH analog currently on the market, Tesamorelin occupies a unique position among GH-axis peptides, providing a clinical reference point for GHRH-based research.
Molecular Profile
- Sequence: Trans-3-hexenoic acid-GHRH(1-44)-NH₂
- Amino acids: 44
- Molecular weight: ~5,135.9 Da
- CAS number: 218949-48-5
- Modification: N-terminal trans-3-hexenoic acid group enhances metabolic stability
- FDA approval: 2010, for HIV-associated lipodystrophy
- Administration: Subcutaneous injection
Mechanism of Action
Tesamorelin activates the GHRH receptor (GHRHR) on anterior pituitary somatotroph cells, stimulating endogenous growth hormone synthesis and secretion. Its mechanism mirrors physiological GHRH signaling (Fridman et al., 2009):
- GH pulsatile release: Amplification of natural GH pulse amplitude, preserving pulsatile secretion patterns
- IGF-1 normalization: Restoration of IGF-1 levels toward youthful ranges in subjects with age-related or disease-related GH decline
- Visceral adipose tissue reduction: GH-mediated lipolysis preferentially targets visceral adipose tissue, which is metabolically distinct from subcutaneous fat
- Feedback preservation: Unlike exogenous GH, Tesamorelin preserves the hypothalamic-pituitary negative feedback loop through somatostatin and IGF-1
Research Area 1: HIV-Associated Lipodystrophy
Tesamorelin's FDA approval was based on two pivotal Phase 3 trials. Falutz et al. (2007) published results demonstrating that Tesamorelin reduced trunk fat by approximately 15% in HIV-infected patients with excess abdominal adiposity, compared to a 5% increase in the placebo group. The effect was specific to visceral adipose tissue, with minimal changes in subcutaneous fat or limb fat.
Falutz et al. (2010) confirmed durability of the effect over 52 weeks of treatment, with sustained visceral fat reduction and improvements in trunk-to-limb fat ratio. IGF-1 levels normalized and patient-reported body image improved significantly.
Research Area 2: Visceral Fat and Metabolic Syndrome
Beyond HIV-associated lipodystrophy, Tesamorelin has been studied for visceral fat reduction in non-HIV populations. Stanley et al. (2014) investigated Tesamorelin in obese subjects with elevated visceral adiposity and demonstrated significant reductions in visceral adipose tissue measured by CT imaging, along with improvements in triglyceride levels.
The preferential mobilization of visceral fat is clinically significant because visceral adipose tissue is the fat depot most strongly associated with insulin resistance, cardiovascular disease, and inflammatory markers.
Research Area 3: Non-Alcoholic Fatty Liver Disease (NAFLD)
Stanley et al. (2014) also reported reductions in liver fat content in Tesamorelin-treated subjects — a finding that has generated significant research interest. Hepatic steatosis (fatty liver) is closely associated with visceral adiposity and represents a growing public health concern.
Fourman et al. (2020) conducted a randomized controlled trial specifically examining Tesamorelin's effects on hepatic fat in HIV-infected individuals with NAFLD. The study demonstrated significant reductions in liver fat fraction measured by MRI, along with improvements in hepatic fibrosis markers, suggesting both fat-clearing and anti-fibrotic effects in the liver.
Research Area 4: Cognitive Function
An emerging area of Tesamorelin research involves cognitive effects. Baker et al. (2012) conducted a randomized controlled trial in healthy older adults and adults with mild cognitive impairment (MCI), demonstrating that Tesamorelin improved executive function and verbal memory. The cognitive improvements correlated with increases in IGF-1 levels, suggesting GH-IGF-1 axis restoration as the mediating mechanism.
These findings are consistent with broader research demonstrating that IGF-1 plays important roles in hippocampal neurogenesis, synaptic plasticity, and neuroprotection, and that age-related GH-IGF-1 decline may contribute to cognitive aging.
Research Area 5: Cardiovascular Biomarkers
Falutz et al. (2008) examined cardiovascular risk markers during Tesamorelin treatment and reported improvements in triglyceride levels and non-HDL cholesterol, with a favorable overall lipid profile shift. The cardiovascular implications are relevant given the association between visceral adiposity and cardiovascular disease risk.
Subsequent analyses have shown that Tesamorelin's cardiometabolic benefits track primarily with visceral fat reduction, supporting the hypothesis that visceral adipose tissue is a primary driver of metabolic cardiovascular risk.
Current Research Status
Tesamorelin remains FDA-approved and commercially available for HIV-associated lipodystrophy. Active research areas include NAFLD/NASH, cognitive aging, and metabolic syndrome in non-HIV populations. Its status as the only FDA-approved GHRH analog provides a uniquely well-characterized clinical profile for a GH-axis peptide, with extensive safety and efficacy data from regulatory-quality clinical trials.
Research Disclaimer
This article is for educational and informational purposes only. BeaCapra supplies research peptides for laboratory and research use. Nothing in this article constitutes medical advice.